Isoflurane anesthesia induces liver injury by regulating the expression of insulin-like growth factor 1

YINGXIAN ZHU1*, XIAOYU XIAO1*, GUOWEI LI2, JUYUAN BU3, WENYING ZHOU4 and SHAOPENG ZHOU1

Departments of ¹Anesthesiology, ²Orthopaedics II, ³General Surgery I and ⁴Center Laboratory,
The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong 519000, P.R. China

Received November 18, 2015; Accepted December 9, 2016

DOI: 10.3892/etm.2017.4157

Abstract. It has been suggested that isoflurane may cause perioperative liver injury. However, the mechanism of its action remains unknown. The purpose of the present study was to determine this possible mechanism. Sprague-Dawley rats were randomly assigned into one of three groups (all n=12): Control group (exposed to mock anesthesia), isoflurane group (exposed to 2% isoflurane for 90 min), and isoflurane + insulin-like growth factor 1 (IGF-1) group (exposed to 2% isoflurane for 90 min and then treated with IGF-1). Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting were conducted to determine the levels of expression of IGF-1 and its receptor IGF-R. Liver necrosis was assessed by histological examination. TUNEL assay was performed to determine the apoptosis of hepatic cells. In addition, the levels of the proteins caspase-3 and B-cell lymphoma-extra large (Bcl-xL) were measured. Compared with the control group, levels of IGF-1 and IGF-1R mRNA and protein were significantly decreased following exposure to isoflurane (all P<0.05). The necrosis rate and liver apoptosis were significantly increased in the group treated with isoflurane alone compared with the control group (P<0.05), but were significantly decreased compared with the isoflurane group following application of IGF-1 (P<0.05). Additionally, isoflurane exposure significantly increased levels of caspase-3 compared with the control group (P<0.05), but decreased levels of Bcl-xL (P<0.05). By contrast, application of IGF-1 reversed these changes. The present study therefore suggests that isoflurane induces liver injury in part by regulating the expression of IGF-1 and that application of IGF-1 may protect against liver injury induced by isoflurane exposure.

Introduction

It has been a long time since the introduction of anesthetic drugs to the clinical application. However, exposure to anesthetic agents may result in adverse outcomes including cellular damage. The anesthetic drugs currently available induce various side effects (1). For example, it has been reported that ~20% patients who receive halothane may have experience nausea, lethargy, and fever side effects (2). The liver is heavily involved in drug metabolism and the majority of anesthetics are metabolized totally or partially, in the liver, explaining why anesthetic drugs induce liver injury (3). Isoflurane is a volatile anesthetic agent, which is widely administered to patients undergoing surgical procedures (4). Isoflurane undergoes minimal biotransformation; however, a wide spectrum of hepatotoxicity ranging from transaminitis to fulminant hepatic failure induced by isoflurane has been observed (5-8).

It has been demonstrated that the oxidative stress response, and hepatic necrosis and apoptosis, are involved in the liver injury mechanism (9,10); however, the exact mechanisms underlying this action have not been elucidated. A number of studies have investigated the role of insulin-like growth factor 1 (IGF-1) in liver disease (11-15). IGF-1 is synthesized in hepatocytes and multiple non-parenchymal cells, and serves an important role in the anabolic and metabolic actions involved in the growth and function of multiple tissues (13,16). Serum IGF-I levels have been regarded as a useful index of hepatocellular dysfunction. Serum IGF-I levels are decreased in chronic liver disease (17,18) and it has been observed that administering IGF-1 may improve liver function (19) and decrease oxidative damage and fibrosis (13). Microarray analysis has suggested that the level of IGF-1 is downregulated following exposure to isoflurane anesthesia (20). Therefore, it has been speculated that IGF-1 may be involved in the liver injury mechanism induced by exposure to isoflurane anesthesia.

To confirm this hypothesis, in the present study, rats were exposed to isoflurane for 90 min then levels of IGF-1 and its receptor (IGF-1R) were measured. Exogenous IGF-1 was subsequently administered to rats to investigate the effect of IGF-1 on liver function, as well as its possible mechanism of action. The results of the present study may provide evidence supporting the use of IGF-1 in the treatment of liver injury induced by anesthesia.
Materials and methods

Animals and grouping. A total of 36 male six-week-old Sprague-Dawley rats, weighing 200-250 g, were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China) and allowed to acclimatize for one week prior to experiments. The rats were randomly assigned into one of three groups: A control group (n=12, exposed to mock anesthesia), an isoflurane group (n=12, exposed to 2% isoflurane for 90 min) and an isoflurane + IGF-1 group (n=12, exposed to 2% isoflurane for 90 min and then administered IGF-1 intervention). The rats were maintained under a standard 12/12-h light/dark cycle in temperature-controlled cages (22±5°C) with a relative humidity of 60±10% and received standard food pellets and distilled water ad libitum. All animals were treated in accordance with the standards of the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (Bethesda, MD, USA) and all protocols were approved by the Ethics Committee on Animals at Sun Yat-Sen University (Zhuhai, China).

Isoflurane exposure and tissue collection. The rats in the isoflurane group were placed in an induction chamber and received 2% isoflurane (Forene; Abbott, Queenborough, Kent, UK)/98% medical grade air (vol/vol) from an anesthesia machine (Fabius CE, Dräger Medical, Lübeck, Germany) for 90 min. Rats in the control group received air/oxygen at identical flow rates. The concentration of isoflurane was monitored continuously with a Datex Capnomac gas-analyzer (Datex-Ohmeda, Helsinki, Finland) throughout anesthesia. The rectal temperature was maintained at 37.0±0.5°C by a heating lamp and pulse oximeter oxygen saturation (SpO₂) was routinely monitored. The rats in the isoflurane + IGF-1 group received anesthetic exposure, then intravenous injections of IGF-1 (20 µg/kg; Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) at different amounts of time (0 and 72 h and 7 days). Thereafter, all animals were sacrificed by decapitation after administration of IGF-1 at 0 and 72 h and 7 days and liver tissues were collected for further analyses.

Histological assessment of liver necrosis. The extent of liver necrosis was determined in 10% neutral buffered formaldehyde-fixed (4°C for 6 h) paraffin-embedded liver sections stained with hematoxylin and eosin, according to a previously described method (21). Briefly, sections were harvested at different times following the application of IGF-1 (0 h, 72 h and 7 days). Sections were deparaffinized, hydrated, stained in alum hematoxylin, differentiated with acid alcohol, washed with tap water, stained with eosin and dehydrated. Sections were then observed under a light microscope (BX51; Olympus Corp., Tokyo, Japan) by a pathologist who was blinded to the groups. Ten high-power fields were randomly collected. The area of necrosis was quantified using ImageJ software version 1.45 (National Institutes of Health). The necrosis rate was calculated as the area of necrosis divided by the total area.

TUNEL assay. A TUNEL assay was performed to determine the apoptosis of hepatic cells in rat livers using a commercially available TUNEL kit (APO-DIRECT™ kit; BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer's instructions. Briefly, sections were fixed with 4% paraformaldehyde for 10 min at room temperature, washed with phosphate-buffered saline (PBS) twice, maintained with 0.1% Triton X-100 in PBS and then incubated with H₂O₂ for 10 min in methanol at room temperature. Sections were then washed with PBS, followed by incubation in 50 µl biotin labeling solution at 37°C for 1 h in a humidified chamber. Following washing in PBS, sections were incubated with labeling termination solution for 5 min at room temperature and washed again. Streptavidin-horseradish peroxidase working solution (50 µl; Novolink Polymer; Leica Microsystems, Ltd., Milton Keynes, UK) was added to the sections at room temperature for 30 min. Subsequently, sections were incubated in diaminobenzidine working solution (Novolink Polymer; Leica Microsystems, Inc.) at room temperature, washed twice with PBS and photographed using a fluorescence microscope (BX50/BX-FLA/DP70; Olympus Corp.).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Levels of IGF-1 and IGF-1R mRNA were measured using standard RT-qPCR techniques. RT-qPCR was performed at least three times. Total RNA was derived from liver tissues using TRizol® (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's instructions. First-strand cDNA was synthesized with the EasyScript® First-Strand cDNA Synthesis SuperMix (TransGen Biotech, Inc., Beijing, China). Amplification reactions were determined using the GeneAmp PCR System 2400 thermal cycler (Applied Biosystems; Thermo Fisher Scientific, Inc.). qPCR was performed using a Quantitect SYBR Green RT-PCR kit (Qiagen SA, Courtaboeuf, France). Primer sequences were as follows: IGF-1, forward 5'-GGT CGGATTGTGTGCGTTGTT-3' and reverse 5'-TCTGAGAGGC GTGGAGA TGTTG-3'; IGF-1R, forward 5'-ACTATGCGCGGT TGCTGGTG-3' and reverse 5'-TGCAAGTTCTGTTGTCG AG-3'; and GAPDH, forward 5'-CTCTGCAACACCAAC TGCTTAG-3' and reverse 5'-AGT GGCAGTGATGCGATG GACT-3'. PCR conditions were as follows: Initial denaturation was performed at 95°C for 15 sec, followed by 30 cycles of denaturation for 30 sec at 95°C, annealing at 61°C for 5 sec, extension at 72°C for 15 sec, and subsequent final extension was performed at 72°C for 10 min. PCR products were run on an 1.2% agarose gel. The GAPDH gene was used as a reference gene. Fold changes relative to GAPDH were calculated using the 2^-ΔΔCq method (22).

Western blot analysis. Tissue was harvested, washed with PBS and homogenized in 10 mM Tris buffer (pH 7.5). Total tissues homogenates were sonicated then centrifuged at 1,000 x g for 20 min at 4°C to extract protein. Protein concentration was assessed using a bicinchoninic acid protein assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Protein samples (20 µg per lane) were resolved with 10% SDS-PAGE. The separated proteins were transferred onto a polyvinylidene fluoride ultrafiltration membrane and the membrane was washed twice with Tris-buffered saline with Tween (TBST). The membranes were immersed in 5% fresh nonfat dry milk in TBST for 2 h at room temperature, washed with TBST and incubated with following polyclonal primary antibodies overnight at 4°C:
Anti-IGF-1 antibody (sc-14221; 1:1,000), anti-IGF-1R antibody (sc-80985; 1:1,000), anti-caspase-3 antibody (sc-271759; 1:1,000), anti-B-cell lymphoma-extralarge (Bcl-xL) antibody (sc-136132; 1:1,000) or anti-GAPDH (sc-293335; 1:1,000). All antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Following washing with TBST, the membrane was incubated with horseradish peroxidase-labeled goat anti-mouse secondary antibody (ZDR-5307; 1:5,000) (Beijing Zhongshan Golden Bridge Biotechnology, Co., Ltd., Beijing, China) for 2 h at room temperature. Finally, bands were visualized using an enhanced chemiluminescence western blotting substrate (Pierce; Thermo Fisher Scientific, Inc.), exposed to an X-ray film (Midwest Scientific, St. Louis, MO, USA), followed by densitometric analysis.

Statistical analysis. Data are represented as the mean ± standard deviation. The differences were compared using Student's t-test (for two groups) or one-way analysis of variance (for three or more groups). All statistical analyses were performed using SPSS software version 16.0 (SPSS, Inc., Chicago, IL, USA). \( P<0.05 \) was considered to indicate a statistically significant difference.

Results

Expression of IGF-1 and IGF-1R following exposure to isoflurane. To evaluate the role of IGF-1 in the liver injury induced by isoflurane, levels of IGF-1 and IGF-1R mRNA and protein were measured following isoflurane exposure for 90 min. The results indicated that compared with the control group, levels of IGF-1 and IGF-1R mRNA (Fig. 1) and protein (Fig. 2) were significantly decreased following isoflurane exposure (all \( P<0.05 \)), indicating that isoflurane significantly inhibited the expression of IGF-1 and IGF-1R.

Liver necrosis rates following application of IGF-1. To assess the protective function of IGF-1 on the liver, IGF-1 was applied following exposure to isoflurane. At 0, 72 h and 7 days, the liver tissues were harvested and the necrosis rate was determined. At 7 days, the necrosis rate was significantly increased in the isoflurane group compared with the control group (\( P<0.05 \)); however, compared with the isoflurane group, the necrosis rate was significantly decreased following the application of IGF-1 (\( P<0.05 \); Fig. 3). The results suggest that IGF-1 application may reduce tissue necrosis to some extent.

Liver apoptosis rates following application of IGF-1. Subsequently, the effect of IGF-1 application on liver apoptosis was evaluated. As presented in Fig. 4, the number of apoptotic cells detected at day 7 were significantly higher following isoflurane exposure than those in the control group (\( P<0.05 \)). However, compared with the isoflurane group, the number of apoptotic cells was reduced in the group receiving IGF-1 (\( P<0.05 \)), demonstrating that IGF-1 application may effectively decrease the rate of apoptosis in the liver.

Expression of caspase-3 and Bcl-xL following application of IGF-1. The mechanism of apoptosis was further investigated. The expression levels of the apoptosis-related proteins caspase-3 and Bcl-xL were determined. It was demonstrated that isoflurane
significantly increased levels of caspase-3 compared with the control group (P<0.05; Fig. 5A), but decreased levels of Bcl-xL (P<0.05; Fig. 5B). However, application of IGF-1 significantly reduced levels of caspase-3 compared with the isoflurane group (P<0.05), but elevated levels of Bcl-xL (P<0.05; Fig. 5A and B). These results indicate that isoflurane induces apoptosis by elevating the expression of pro-apoptotic proteins (caspase-3), and reducing the expression of anti-apoptotic proteins (Bcl-xL). By contrast, IGF-1 treatment appeared to inhibit apoptosis by decreasing the expression of the pro-apoptotic protein caspase-3, and increasing the expression of the anti-apoptotic protein Bcl-xL (Fig. 5).

**Discussion**

In the present study, it was demonstrated that exposure to isoflurane may induce liver injury by stimulating liver necrosis and apoptosis, and significantly decreasing levels of IGF-1 and IGF-IR mRNA and protein. Application of IGF-1 following exposure to isoflurane alleviates liver injury by decreasing the rates of liver necrosis and apoptosis. The results of the present study indicate that isoflurane induces liver injury by regulating the expression of IGF-1 and application of IGF-1 may protect against the liver injury induced by isoflurane exposure.

Isoflurane is a halogenated volatile anesthetic, which has generally been considered to be a non-hepatotoxic alternative to halothane (23); nonetheless, an increasing number of cases of hepatic dysfunction following the administration of isoflurane have been reported (24,25). Two distinctive types of hepatotoxicity, mild injury and fulminant hepatotoxicity, have been observed following exposure to halogenated anesthetic agents. Mild injury is associated with mild increases in the levels of aminotransferase enzymes, whereas fulminant hepatotoxicity is characterized by marked increases in levels of liver enzymes and bilirubin and results in mass hepatic necrosis (26). In addition, apoptosis (programmed cell death) has been regarded as a primary mechanism of liver injury that occurs following anesthetic administration (3,27) and may result in mass apoptosis (28). Edmands et al (20) found that exposure to isoflurane anesthesia downregulated IGF-1 levels, indicating that there may be a possible association between isoflurane anesthesia and IGF-1. It has been suggested that IGF-1 and its receptor IGF-1R serve important roles in the liver (29). Decreased serum levels of IGF-1 are associated with chronic liver disease and the levels of circulating IGF-1 may be correlated with the degree of hepatocellular dysfunction (30). The effects of the IGF-1 are mediated through the IGF-1R; however, IGF-1 has little direct effect on hepatocyte function as low levels of IGF-1R are expressed by hepatocytes in normal conditions (31). However, overexpression of IGF-1R has been detected in chronic hepatitis C (32), chronic hepatitis B and liver cirrhosis (33). A number of potential underlying mechanisms may be responsible for the effects of IGF-1 on the liver. Insulin resistance (34), oxidative stress and mitochondrial dysfunction may be responsible for the development of liver diseases (35). It has been demonstrated that IGF-1 improves
isoflurane induces liver injury by regulating the expression of Bcl-xL levels, suggesting that apoptosis was prevented by significantly downregulated levels of caspase-3 but elevated was induced by isoflurane. However, application of IGF-1 were significantly increased by isoflurane, whereas levels of stimulation of caspase-9 (46) and caspase-3 (47). In the present study, it was demonstrated that levels of caspase-3 were significantly increased by isoflurane, whereas levels of Bcl-xL were significantly decreased, indicating that apoptosis was induced by isoflurane. However, application of IGF-1 significantly downregulated levels of caspase-3 but elevated Bcl-xL levels, suggesting that apoptosis was prevented by IGF-1.

In conclusion, the results of the present study suggest that isoflurane induces liver injury by regulating the expression of IGF-1. Application of IGF-1 may therefore protect against liver injury induced by isoflurane exposure.

References


